TS-065860 — The Need: Cancer remains one of the most pressing medical challenges of our time, demanding innovative solutions to enhance treatment efficacy while minimizing systemic toxicity. Conventional chemotherapy agents often suffer from poor solubility, instability, and indiscriminate cytotoxicity, necessi…

TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…

TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…

TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…

TS-064187 — The Need In the culinary and pharmaceutical realms, the need for a groundbreaking solution to modulate flavor and alleviate sensory perceptions is crucial. Businesses seek innovative ways to enhance consumer experiences by addressing pungency in foods and alleviating burn or pain sensations in phar…

TS-062571 — The Need Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…

TS-062439 — The Need: Addressing the Growing Threat of Gram-Negative Bacterial Infections Gram-negative bacterial pathogens, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are responsible for more than 35% of common hospital-acquired infections. These no…

TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…

TS-062420 — The Need: Addressing Nutritional Challenges in Cystic Fibrosis Cystic Fibrosis (CF) presents significant nutritional challenges for individuals living with the condition. Due to the increased energy requirements and difficulties in nutrient absorption, CF patients often struggle to maintain adequat…

TS-062355 — The Need: In today's fast-paced and demanding world, the need for innovative solutions that enhance mental well-being and cognitive performance has never been greater. Recent scientific discoveries have highlighted the crucial role of the gut-brain connection in influencing human behavior and …

TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…

TS-062232 — The Need The current demand in the market is for a safe and effective SARS-CoV-2 vaccine that can induce both antibody and T cell responses. The traditional understanding of antibody-based immunity is incomplete, as virus-infected cells are eliminated with the help of T cells. To combat SARS-CoV-2 …

TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…

TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…

TS-037753 — A method to create vaccines for pneumoviruses, using recombinant viruses.

TS-037675 — Novel method of using live attenuated vaccines to prevent infection of hMVP.

TS-037664 — A live recombinant vesicular stomatitis virus (VSV)-vector vaccine composition for human norovirus.

TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.

TS-032198 — A parenteral administration of a naturally occurring chemical used to treat influenza­-induced hypoxemia, lung dysfunction, and acute respiratory distress syndrome (ARDS). This treatment could also be potentially useful in treating ARDS from other causes.

TS-015239 — Enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.